CCL

Összesen 23 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM004656
035-os BibID:WOS:000088961100053
Első szerző:Bacsó Zsolt (biofizikus)
Cím:The DNA of annexin V-binding apoptotic cells is highly fragmented / Bacso, Z., Everson, R. B., Eliason, J. F.
Dátum:2000
Megjegyzések:Jurkat leukemia cells induced to undergo apoptosis by treatment with an antibody against the Fas receptor have two annexin V (AV)-binding subpopulations: (a) single-positive cells that bind AV but not propidium iodide (PI); and (b) double-positive cells that bind AV and PI. The single-positive population is thought to represent an early stage of apoptosis. We have examined the relationship between AV binding and a classical characteristic of apoptosis, DNA fragmentation. Time course studies with Jurkat cells treated for 1, 2, or 4 h with anti-Fas indicated that the proportion of AV-binding cells was increased after 2 h. A significant increase in DNA fragmentation was observed only at 4 h as measured by the mean tail moment determined with the alkaline single cell gel electrophoresis (comet) assay. This correlation suggests a temporal relationship between the two parameters, but does not provide direct evidence of what happens in individual cells. We developed a method to measure fluorescent markers of cellular structure or function with a laser scanning cytometer and then perform the comet assay on the same cells. Cells in each AV-binding subpopulation were re-examined before and after electrophoresis. Most AV-/PI- cells had no DNA damage, although a few cells showed a pattern of damage characteristic for apoptosis. Double-positive cells all had damaged DNA; approximately half had the apoptotic pattern, and the rest had a pattern typical for necrosis. Nearly all of the single-positive cells had damaged DNA with the apoptotic pattern. Both AV-positive populations contained cells with little or no detectable DNA after electrophoresis, indicating that the DNA was highly fragmented. These results indicate that AV binding is an excellent marker for apoptotic cells, but that these cells already have fragmented DNA.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Annexin V
Antibodies
Antibodies, Monoclonal
Antigens, CD95
Apoptosis
Cell Membrane
Cells
Comet Assay
cytology
Dna
DNA Damage
DNA Fragmentation
DNA, Neoplasm
Dyes
Flow Cytometry
Human
immunology
Jurkat Cells
metabolism
Necrosis
pharmacology
Phosphatidylserines
physiology
Propidium
Support, Non-U.S.Gov't
Tumor Cells, Cultured
külföldön készült közlemény
Megjelenés:Cancer research. - 60 : 16 (2000), p. 4623-4628. -
További szerzők:Everson, Richard B. Eliason, James F.
Internet cím:elektronikus változat
Borító:

2.

001-es BibID:BIBFORM023325
Első szerző:Carracedo, Alma
Cím:FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors / Alma Carracedo, Kristof Egervari, Marta Salido, Federico Rojo, Josep M. Corominas, Montserrat Arumi, Cristina Corzo, Ignacio Tusquets, Blanca Espinet, Ana Rovira, Joan Albanell, Zoltan Szollosi, Sergi Serrano, Francesc Solé
Dátum:2009
Tárgyszavak:Orvostudományok Klinikai orvostudományok levél
Megjelenés:Breast Cancer Research and Treatment. - 11 : 2 (2009), p. 402. -
További szerzők:Egervári Kristóf (1983-) (patológus) Salido, Marta Rojo, Federico Corominas, Josep M. Arumi, Montserrat Corzo, Cristina Tusquets, Ignacio Espinet, Blanca Rovira, Ana Albanell, Joan Szöllősi Zoltán Serrano, Sergi Solé, Francesc
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

3.

001-es BibID:BIBFORM042782
Első szerző:Cauley, Jane A.
Cím:Continued breast cancer risk reduction in postmenopausal women treated with raloxifene : 4-year results from the MORE trial / Jane A. Cauley, Larry Norton, Marc E. Lippman, Stephen Eckert, Kathryn A. Krueger, David W. Purdie, Jordi Farrerons,Avraham Karasik, Dan Mellstrom, Kong Wah Ng, Jan J. Stepan, Trevor J. Powles, Monica Morrow, Alberto Costa, Sheryl L. Silfen, Erin L. Walls, Henry Schmitt, Douglas B. Muchmore, V. Craig Jordan, [The Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators]
Dátum:2001
ISSN:0167-6806
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Breast cancer research and treatment. - 65 : 2 (2001), p. 125-134. -
További szerzők:Norton, Larry Lippman, Marc E. Eckert, Stephen Krueger, Kathryn Purdie, David W. Farrerons, Jordi Karasik, Avraham Mellstrom, Dan Wah Ng, Kong Stepan, Jan Powles, Trevor J. Morrow, Monica Costa, Alberto Silfen, Sheryl L. Walls, Erin L. Schmitt, Henry Muchmore, Douglas B. Jordan, V. Craig Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos) The Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM066525
Első szerző:Chirgwin, Jacquie
Cím:The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause / Jacquie Chirgwin, Zhuoxin Sun, Ian Smith, Karen N. Price, Beat Thürlimann, Bent Ejlertsen, Hervé Bonnefoi, Meredith M. Regan, Aron Goldhirsch, Alan S. Coates, BIG 1-98 Collaborative Group, International Breast Cancer Study Groups
Dátum:2012
ISSN:0167-6806
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Breast Cancer Research And Treatment 131 (2012), p. 295-306. -
További szerzők:Sun, Zhuoxin Smith, Ian Price, Karen N. Thürlimann, Beat Ejlertsen, Bent Bonnefoi, Hervé Regan, Meredith M. Goldhirsch, Aron Coates, Alan S. Horváth Zsolt (1964-) (onkológus, belgyógyász, klinikai farmakológus) BIG 1-98 Collaborative Group International Breast Cancer Study Group
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM009099
Első szerző:Czifra Gabriella (élettanász)
Cím:Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma / Czifra, G., Varga, A., Nyeste, K., Marincsak, R., Toth, B. I., Kovacs, I., Kovacs, L., Biro, T.
Dátum:2009
ISSN:0171-5216
Megjegyzések:Recently, functional cannabinoid receptor-1 (CB1) and vanilloid receptor-1 (TRPV1) have been described in human prostate and prostate cancer-derived cell lines where the activation of the receptors resulted in inhibition of cellular growth. We, however, lack the description of the expression of these molecules in human prostate cancer (PCC) and in benign prostate hyperplasia (BPH). METHODS: Therefore, immunohistochemistry, Western blotting, and quantitative "real-time Q-PCR were performed to define the expressions of CB1 and TRPV1 in healthy and diseased prostate tissues. RESULTS: CB1 was identified in epithelial and smooth muscle cells types of the human prostate, whereas TRPV1 was exclusively localized to the mucosal cells. We also found that the expression of CB1 and TRPV1 (both at the protein and mRNA levels) were significantly up-regulated in PCC. However, while the increased expression of TRPV1 showed a proper correlation with increasing PCC tumor grades, such phenomenon was not observed with CB1. In addition, we also measured markedly elevated CB1 levels in BPH tissues whilst the expression of TRPV1 was not altered when compared to healthy control prostate. CONCLUSIONS: Our findings strongly argue for that (1) the CB1 and TRPV1 molecules as well as their ligands may indeed possess a promising future role in the treatment of PCC; (2) TRPV1 may also serve as a prognostic factor in PCC; and (3) CB1 may act as a potential target molecule in the therapeutic management of BPH.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of Cancer Research and Clinical Oncology. - 135 : 4 (2009), p. 507-514. -
További szerzők:Varga Attila (1949-) (urológus, andrológus) Nyeste Katalin Marincsák Rita (1979-) (fogszakorvos) Tóth István Balázs (1978-) (élettanász) Kovács Ilona (1965-) (patológus) Kovács László (1939-) (élettanász) Bíró Tamás (1968-) (élettanász)
Internet cím:DOI
elektronikus változat
elektronikus változat
Borító:

6.

001-es BibID:BIBFORM065549
Első szerző:Illés Árpád (belgyógyász, haematológus, onkológus)
Cím:Treatment Options of Mature, Nodal T-Cell Lymphomas / Illés Á., Miltényi Z.
Dátum:2016
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Austin Journal of Cancer and Clinical Research 3 : 1 (2016), p. 1-7. -
További szerzők:Miltényi Zsófia (1975-) (belgyógyász, haematológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM040147
Első szerző:Jacob, Karine
Cím:Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas / Jacob, K., Quang-Khuong, D.-A., Jones, D. T. W., Witt, H., Lambert, S., Albrecht, S., Witt, O., Vezina, C., Shirinian, M., Faury, D., Garami, M., Hauser, P., Klekner, A., Bognar, L., Farmer, J.-P., Montes, J.-L., Atkinson, J., Hawkins, C., Korshunov, A., Collins, V. P., Pfister, S. M., Tabori, U., Jabado, N.
Dátum:2011
ISSN:1078-0432
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Clinical Cancer Research. - 17 : 14 (2011), p. 4650-4660. -
További szerzők:Quang-Khuong, D.-A. Jones, David T. W. Witt, Hendrik Lambert, Sally Albrecht, Stephen Witt, Olaf Vezina, C. Shirinian, Margret Faury, Damien Garami Miklós Hauser Péter Klekner Álmos (1970-) (idegsebész) Bognár László (1958-) (idegsebész, gyermekidegsebész) Farmer, Jean-Pierre Montes, Jose-Luis Atkinson, J. Hawkins, Cynthia E. Korshunov, Andrey Collins, V. Peter Pfister, Stefan M. Tabori, Uri Jabado, Nada
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM103424
035-os BibID:(WOS)000837443600001 (Scopus)85134360196
Első szerző:Jdeed, Sham
Cím:The Role of ARID1A in the Nonestrogenic Modulation of IGF-1 Signaling / Jdeed Sham, Erdős Edina, Bálint Bálint L., Uray Iván P.
Dátum:2022
ISSN:1541-7786
Megjegyzések:Gaining pharmacologic access to the potential of ARID1A, a tumor suppressor protein, to mediate transcriptional control over cancer gene expression is an unresolved challenge. Retinoid X receptor ligands are pleiotropic, incompletely understood tools that regulate breast epithelial cell proliferation and differentiation. We found that low-dose bexarotene (Bex) combined with the nonselective beta-blocker carvedilol (Carv) reduces proliferation of MCF10DCIS.com cells and markedly suppresses ARID1A levels. Similarly, Carv synergized with Bex in MCF-7 cells to suppress cell growth. Chromatin immunoprecipitation sequencing analysis revealed that under nonestrogenic conditions Bex ? Carv alters the concerted genomic distribution of the chromatin remodeler ARID1A and acetylated histone H3K27, at sites related to insulinlike growth factor (IGF) signaling. Several distinct sites of ARID1A enrichment were identified in the IGF-1 receptor and IRS1 genes, associated with a suppression of both proteins. The knock-down of ARID1A increased IGF-1R levels, prevented IGF-1R and IRS1 suppression upon Bex ? Carv, and stimulated proliferation. In vitro IGF-1 receptor neutralizing antibody suppressed cell growth, while elevated IGF-1R or IRS1 expression was associated with poor survival of patients with ER-negative breast cancer. Our study demonstrates direct impact of ARID1A redistribution on the expression and growth regulation of IGF-1? related genes, induced by repurposed clinical drugs under nonestrogenic conditions.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
ARID1A
IGF-I
rexinoid
growth suppression
Megjelenés:Molecular Cancer Research. - 20 : 7 (2022), p. 1071-1082. -
További szerzők:Erdős Edina (1989-) (klinikai laboratóriumi kutató) Bálint Bálint László (1971-) (kutató orvos) Uray Iván Péter (1970-) (kutatóorvos)
Pályázati támogatás:NKFIH-K129218
OTKA
GINOP-2.3.2-15-2016-00020
GINOP
EFOP-3.6.1-16-2016-00022
EFOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM054863
Első szerző:Mezey Géza (idegsebész)
Cím:Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes / Géza Mezey, Andrea Treszl, Andrew V. Schally, Normann L. Block, Laura Vízkeleti, Alíz Juhász, Álmos Klekner, János Nagy, Margit Balázs, Gábor Halmos, László Bognár
Dátum:2014
ISSN:0171-5216
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
GHRH
pGHRHR
Splice variants
SV1
EGFR
PTEN?
Human glioblastoma
Megjelenés:Journal of Cancer Research and Clinical Oncology. - 140 : 10 (2014), p. 1641-1649. -
További szerzők:Treszl Andrea (1974-) (molekuláris biológus) Schally, Andrew Victor Block, Norman L. Vízkeleti Laura (1984-) (molekuláris biológus, genetikus) Juhász Alíz (1977-) (molekuláris biológus) Klekner Álmos (1970-) (idegsebész) Nagy János (1956-) (matematikus) Balázs Margit (1952-) (sejtbiológus, molekuláris genetikus) Halmos Gábor (1962-) (gyógyszerész, receptorfarmakológus, experimentális onkológus) Bognár László (1958-) (idegsebész, gyermekidegsebész)
Pályázati támogatás:TÁMOP-4.2.2.A-11/1/KONV-2012-0031
TÁMOP
TÁMOP-4.2.2.A-11/1/KONV-2012-0025 (G.H.)
TÁMOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM004879
Első szerző:Nagy Péter (biofizikus)
Cím:Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line / Nagy, P., Friedlander, E., Tanner, M., Kapanen, A. I., Carraway, K. L., Isola, J., Jovin, T. M.
Dátum:2005
ISSN:0008-5472
Megjegyzések:Overexpression of erbB2 in breast tumors is associated with poor prognosis and is a target of receptor-oriented cancer therapy. Trastuzumab (Herceptin), a monoclonal antibody against a membrane-proximal epitope in the extracellular region of erbB2, shows a therapeutic effect against a fraction of erbB2-amplified breast tumors. Unfortunately, resistance to Herceptin is common, and its cause is as yet unclear. Here we investigated the properties of erbB2 in a Herceptin-resistant cell line, JIMT-1, established from a breast cancer patient showing erbB2 gene amplification and primary resistance to Herceptin. The expression profile of erbB proteins, Herceptin-induced erbB2 internalization, and down-regulation in JIMT-1 were similar to those in Herceptin-sensitive lines. However, the mean number of Herceptin Mab binding sites in JIMT-1 was 1/5 that of the expressed erbB2 molecules, although 5% to 10% of the cells showed a approximately 10-fold higher Herceptin binding than the main population. Herceptin Fab and Mab 2C4, an antibody binding to an epitope in the ectodomain further removed from the membrane, bound more efficiently to JIMT-1 cells than Herceptin Mab, implying that erbB2 was partly masked. The expression of MUC4, a membrane-associated mucin that according to reports contributes to the masking of membrane proteins, was higher in JIMT-1 than in Herceptin-sensitive lines, and its level was inversely correlated with the Herceptin binding capacity of single cells. Knockdown of MUC4 expression by RNA interference increased the binding of Herceptin. Western blotting showed a low level of proteolytic processing, shedding, and tyrosine phosphorylation of erbB2 in JIMT-1. The latter finding may explain its Herceptin-resistant phenotype characterizing both the low and high Herceptin binding subpopulations. We conclude that masking of erbB2 in JIMT-1 leads to diminished Herceptin binding and isolation of erbB2 from its normal interaction and activation partners.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Antibodies
Antibodies,Monoclonal
Antineoplastic Agents
Binding Sites
biosynthesis
Breast Neoplasms
Cell Line
Cell Line,Tumor
Cells
chemistry
Down-Regulation
Drug Resistance,Neoplasm
drug therapy
Enzyme Activation
enzymology
Epitopes
Gene Amplification
Humans
immunology
Membrane Proteins
metabolism
Metalloproteases
Mucins
pharmacology
Phenotype
Phosphorylation
Proteins
Receptor,erbB-2
Research
Support
therapy
Tyrosine
Megjelenés:Cancer Research. - 65 : 2 (2005), p. 473-482. -
További szerzők:Friedländer Elza (1980-) (biofizikus) Tanner, Minna Kapanen, Anita I. Carraway, Kermit L. Isola, Jorma Jovin, Thomas M.
Internet cím:elektronikus változat
Borító:

11.

001-es BibID:BIBFORM082873
035-os BibID:(WOS)000505064300029 (Scopus)85077463101
Első szerző:Papp Tamás (orvos)
Cím:Disorders of neural crest derivates in oncoradiological practice / Papp Tamas, Ferenczi Zsuzsanna, Petro Matyas, Meszar Zoltan, Kepes Zita, Berenyi Ervin
Dátum:2019
ISSN:2218-676X 2219-6803
Megjegyzések:Hundreds of articles discuss the imaging characteristics and molecular background of prominent gastrointestinal (GI) motility disorders and tumors of the peripheral nervous system, but according to our knowledge an article focusing on the classification and developmental background of these heterogeneous diseases is not to be found. Our aim is to give insight on the common features of several diseases and tumors, starting with their common source of origin, the neural crest (NC). The NC is a transient cell population of the embryo, which differentiates into several organs/structures of our body (sympathetic trunk, adrenal medulla). Although the incidence of the individual tumors of NC cells is not high by themselves, the summation of these incidences may be relevant in the daily routine. In the introduction we mention the most prominent developmental routes and molecular pathways of NC cells, which is crucial to understand the pathogenesis and the wide range of involved cell types from the colon to the adrenal gland. We summarized the most important, useful pathological findings and imaging techniques from the X-ray to the positron emission tomography-computed tomography (CT) in order to help the identification of these diseases. This article may help to better understand NC lineage and its unique, diverse role during ontogeny, which may influence the radiologists to change several convictions, or understand better the background and/or connections of a wide range of tumors and syndromes.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Developmental disorders
embryology
neural crest (NC)
oncology
radiology
Megjelenés:Translational Cancer Research. - 8 : 8 (2019), p. 2916-2923. -
További szerzők:Ferenczi Zsuzsanna Petró Mátyás (1985-) (radiológus) Mészár Zoltán Mihály (1977-) (agrármérnök) Képes Zita (1991-) (orvos) Berényi Ervin (1964-) (radiológus)
Pályázati támogatás:KTIA_NAP_13-1-2013-0001
Egyéb
2017-1.2.1-NKP-2017-00002
Egyéb
NKFI-108467
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM073511
035-os BibID:(WoS)000430975800014 (Scopus)85042226122
Első szerző:Pinczés László Imre (általános orvos)
Cím:Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late : a comprehensive analysis of late relapse in Hodgkin lymphoma / László Pinczés, Zsófia Miltényi, Árpád Illés
Dátum:2018
ISSN:0171-5216
Megjegyzések:PurposeMajority of relapses in Hodgkin lymphoma (HL) occur within 3 years after initial treatment, late relapses (LR), happening 5 or more years after first diagnosis is rare events. Neither clinical characteristics, risk factors, nor optimal treatment is well described for LR patients. Our aim was to provide a comprehensive analysis on the LR of HL to outline a patient population at risk of relapsing late.Patients and methods637 HL patients were treated at the University of Debrecen between 1981 and 2010. Patient data was evaluated retrospectively. Survival analysis was performed using the Kaplan?Meier method and odds ratios (OR) were identified by binary logistic regression models.ResultsWith a median observational time of 9.08 years 584 (91%) HL patients achieved complete remission (CR) after first line treatment. Relapse occurred in 176 (28%) patients, 26 (4%) of them 5 or more years after first diagnosis. With multivariable analysis, initial diagnosis before the age of 24 (p?<?0.001), initial presentation between 1981 and 1990 or 1991?2000 (p?=?0.025 and p?=?0.023, respectively) and first line treatment with radiotherapy only (p?=?0.034) were identified as independent risk factors for LR. We observed a significantly impaired OS for patients with early relapse HL compared to those in long-term remission or experiencing LR (p?<?0.001).ConclusionLate relapse of HL presents with clinical characteristics very similar to primary disease and appears to have a good prognosis. First diagnosis in childhood or young adulthood and first line treatment before the ABVD era increases the risk of relapsing late.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Hodgkin
Megjelenés:Journal Of Cancer Research And Clinical Oncology. - 144 : 5 (2018), p. 935-943. -
További szerzők:Miltényi Zsófia (1975-) (belgyógyász, haematológus) Illés Árpád (1959-) (belgyógyász, haematológus, onkológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.